Followers | 603 |
Posts | 29843 |
Boards Moderated | 1 |
Alias Born | 01/30/2012 |
Friday, August 04, 2023 6:18:04 PM
The existing tests take at least 5 days. This test comes back with the results in 3-5 hours. Also using this test they don’t need to separate out anything like plasma or anything. All they need is 4ml of whole blood - meaning what comes out of your arm into the needle then into the test tube and only 4ml of it.
There’s approximately 350,000 Sepsis infections in the USA alone every year.
The US Government will subsidise the cost of the test for the first $97.50.
Also, the test already has the CE mark so it’s approved for use in the European Union. So that’s a population of 350m. Then the USA population is at least 320m last time I checked.
One debt holder has swapped $10m worth of debt for equity in the company and there’s a guy on StockTwits who between himself and the largest institutional investor has loaded up on another 10m shares today according to his posts.
Then they have a strong pipeline of other products as well.
But here’s the thing. Just remember this is a diagnostic test getting approved. It’s not a drug going through Phase I trials etc etc.
Just think about it. The FDA wouldn’t ever fast track anything unless it was already quite likely to get approved.
This is a blood test. All they need to do is prove it works with independent data to get the approval.
Well worth taking a look at the company website.
Also (almost forgot) the CEO is a survivor of a Sepsis infection himself and that is why he sought out the company. It took several days for his infection to be diagnosed and the correct treatment started for the antibiotic resistant infection that he had.
My post are my opinion only. You should do your own due diligence before investing in any stock or take professional advice. I am not an investment advisor. Kind Regards.
Recent TTOO News
- T2 Biosystems Announces Commercial Expansion Through Hong Kong and Macau Distributor • GlobeNewswire Inc. • 06/25/2024 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 06/05/2024 04:15:05 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/25/2024 01:04:14 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:49:54 PM
- T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements • GlobeNewswire Inc. • 05/22/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 11:00:55 AM
- T2 Biosystems Announces Closing of $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 05/17/2024 08:05:00 PM
- T2 Biosystems Announces $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 05/15/2024 11:00:00 AM
- T2 Biosystems Announces CRG’s Conversion from Preferred Stock to Common Stock • GlobeNewswire Inc. • 05/14/2024 09:00:00 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 05/14/2024 08:55:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:43:56 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/13/2024 11:21:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 10:19:50 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/07/2024 11:46:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 08:57:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:48:00 PM
- T2 Biosystems Announces Letter of Intent to Enter Strategic Partnership for Lyme Disease • GlobeNewswire Inc. • 05/07/2024 01:00:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/06/2024 09:27:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:24:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2024 09:19:02 PM
- T2 Biosystems Announces First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/06/2024 08:34:38 PM
- T2 Biosystems Announces Commercial Expansion Through Middle East Distributor • GlobeNewswire Inc. • 05/06/2024 08:34:16 PM
- T2 Biosystems Announces the Conversion of an Additional $15 Million of CRG Term Loan into Equity • GlobeNewswire Inc. • 05/06/2024 08:29:41 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/06/2024 11:48:38 AM
- T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024 • GlobeNewswire Inc. • 04/24/2024 01:00:00 PM
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM